Scientists have identified a promising new biomarker that may greatly improve how doctors predict the behavior of bladder cancer and determine which patients will benefit most from immunotherapy. The protein, called ALYREF, appears to play a complex role. It is linked to faster-growing, more aggressive tumors, yet it also signals a better chance of responding well to immune checkpoint inhibitor (ICI) therapy.
Bladder cancer is difficult to manage because its progression differs widely between patients. Many current clinical tools cannot reliably predict outcomes or treatment response, especially as immunotherapy becomes more common. The discovery of ALYREF’s importance may help address these limitations.
How Researchers Studied ALYREF
The research team used a combination of large pan-cancer data analysis and testing on real patient samples. They measured ALYREF levels in tumor tissues with RT-qPCR, immunohistochemistry, and Western blot methods. They then examined how these levels related to patient survival and disease stage.
Researchers also studied circulating tumor cells (CTCs)—cancer cells that enter the bloodstream—to understand whether ALYREF is connected to the cancer’s ability to spread. Further laboratory experiments using T24 bladder cancer cells tested whether ALYREF directly increases cancer cell movement.
A Dual Role in Bladder Cancer
Findings showed that ALYREF levels were much higher in bladder cancer tissues than in normal tissues. High ALYREF expression was strongly linked to advanced tumor grade and poorer overall survival. Patients with high ALYREF also had more circulating tumor cells, suggesting a greater risk of metastasis. In the lab, increasing ALYREF made cancer cells migrate and invade more easily, confirming its role in promoting tumor spread.
However, the study revealed a surprising insight: patients with high ALYREF expression responded better to immunotherapy. This suggests that ALYREF not only marks aggressive disease but may also help identify patients who are more likely to succeed with ICI treatment.
What This Means for Patient Care
Researchers believe ALYREF could help doctors classify bladder cancer patients more accurately. It may point out those with a higher risk of metastasis, while also identifying patients who would benefit most from immunotherapy. Although more research is needed, these findings offer a promising step toward more personalised and effective treatment strategies for bladder cancer.
Related topics
